/
CAPR
$23.80-$2.64 (-9.98%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.5B
58M shares
52-week range
$4.30 – $40.37
54% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$18.67
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $1.0M | $310.3K | $244.9K | $2.6M | $25.2M | $22.3M | $0 |
| Cost of revenue | $0 | $5.1M | $0 | $0 | $21.8M | $36.4M | $50.0M | $0 |
| Gross profit | $1.7M | −$4.1M | $310.3K | $244.9K | −$19.3M | −$11.3M | −$27.7M | $0 |
| Gross margin | 100.0% | -411.6% | 100.0% | 100.0% | -755.1% | -44.8% | -124.4% | — |
| R&D | $12.1M | $5.1M | $8.5M | $13.6M | $21.8M | $36.4M | $50.0M | $84.5M |
| Operating income | −$15.3M | −$7.7M | −$13.7M | −$20.9M | −$29.7M | −$24.1M | −$42.6M | −$108.1M |
| EBITDA | −$15.2M | −$7.6M | −$13.5M | −$19.8M | −$28.5M | −$21.2M | −$39.0M | −$100.1M |
| Net income | −$15.2M | −$7.6M | −$13.7M | −$20.0M | −$29.0M | −$22.3M | −$40.5M | −$105.0M |
| Net margin | -909.1% | -760.4% | -4401.9% | -8175.9% | -1137.4% | -88.5% | -181.7% | — |
| EPS (diluted) | -5.17 | -2.06 | -0.88 | -0.87 | -1.18 | -0.83 | -1.15 | -2.26 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $131M | $-0.23 | $-1.19–$0.81 | 8 |
| 2027 | $117M | $-0.69 | $-2.43–$0.59 | 7 |
| 2028 | $321M | $2.11 | $0.60–$5.04 | 4 |
| 2029 | $451M | $3.57 | $-0.77–$9.13 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$5.77
Price
$23.80
Implied downside
-76%
Peer comparison
Capricor Therapeutics Inc
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
www.capricor.com- Employees
- 231
- IPO / List date
- Jun 20, 2002
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds CAPR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-06-30 | 137,500 | $655.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2019-06-05 | 1-for-10reverse |
| 2005-04-05 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded CAPR yet.
